# Study in Taiwanese Subjects Identified as CYP2C19 Poor and Extensive Metabolizers Receiving Rosuvastatin

> **NCT00766025** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 50 (estimated)

## Conditions studied

- CYP2C19 Poor
- Extensive Metabolizers

## Interventions

- **DRUG:** Rosuvastatin Calcium

## Key facts

- **NCT ID:** NCT00766025
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** —
- **Final completion:** 2009-02
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2009-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00766025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00766025, "Study in Taiwanese Subjects Identified as CYP2C19 Poor and Extensive Metabolizers Receiving Rosuvastatin". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00766025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*